Germany · Delayed Price · Currency is EUR Solasia Pharma K.K. Statistics
Total Valuation
FRA:9SO has a market cap or net worth of EUR 44.72 million. The enterprise value is 37.64 million.
| Market Cap | 44.72M |
| Enterprise Value | 37.64M |
Important Dates
The last earnings date was Friday, February 13, 2026.
| Earnings Date | Feb 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 263.30M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +19.53% |
| Shares Change (QoQ) | +3.40% |
| Owned by Insiders (%) | 2.10% |
| Owned by Institutions (%) | -1.03% |
| Float | 226.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19.19 |
| PB Ratio | 4.70 |
| P/TBV Ratio | 4.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.91 |
| EV / Sales | 16.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.06, with a Debt / Equity ratio of 0.05.
| Current Ratio | 6.06 |
| Quick Ratio | 5.64 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -61.36 |
Financial Efficiency
Return on equity (ROE) is -60.25% and return on invested capital (ROIC) is -35.46%.
| Return on Equity (ROE) | -60.25% |
| Return on Assets (ROA) | -30.62% |
| Return on Invested Capital (ROIC) | -35.46% |
| Return on Capital Employed (ROCE) | -46.86% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 101,322 |
| Profits Per Employee | -206,895 |
| Employee Count | 23 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 1.84 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.29% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -30.29% |
| 50-Day Moving Average | 0.14 |
| 200-Day Moving Average | 0.17 |
| Relative Strength Index (RSI) | 52.77 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:9SO had revenue of EUR 2.33 million and -4.76 million in losses. Loss per share was -0.02.
| Revenue | 2.33M |
| Gross Profit | 1.13M |
| Operating Income | -4.67M |
| Pretax Income | -4.76M |
| Net Income | -4.76M |
| EBITDA | -4.47M |
| EBIT | -4.67M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 7.53 million in cash and 516,057 in debt, with a net cash position of 7.02 million.
| Cash & Cash Equivalents | 7.53M |
| Total Debt | 516,057 |
| Net Cash | 7.02M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 9.52M |
| Book Value Per Share | 0.04 |
| Working Capital | 8.57M |
Cash Flow
| Operating Cash Flow | -4.60M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 48.48%, with operating and profit margins of -200.23% and -204.20%.
| Gross Margin | 48.48% |
| Operating Margin | -200.23% |
| Pretax Margin | -204.20% |
| Profit Margin | -204.20% |
| EBITDA Margin | -191.61% |
| EBIT Margin | -200.23% |
| FCF Margin | n/a |
Dividends & Yields
FRA:9SO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.53% |
| Shareholder Yield | -19.53% |
| Earnings Yield | -10.64% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:9SO has an Altman Z-Score of 11.91 and a Piotroski F-Score of 2.
| Altman Z-Score | 11.91 |
| Piotroski F-Score | 2 |